Four developments that shaped September
One feature per therapeutic area, chosen by patient impact from the studies and FDA approvals ENCLAI reported in September 2026. Every number checked against its source sentence.
Dr Natalya Mathur · Dr Anjali Mathur · Dr Mathur G · ENCLAI
September 2026 · 15 pages · Published by ENCLAI
In this issue
Oncology · Randomised trial, Phase 3Retlirafusp alfa plus chemotherapy extends survival in HER2-negative gastric cancerRead the full article →Respiratory · Randomised trial, Phase 3Inhaled treprostinil slows lung function loss in IPFRead the full article →Neurology · ApprovalIsembyld: FDA approval for spinal muscular atrophy in patients on SMN2 therapyRead the full article →Vaccines · Randomised trial, Phase 3Silevimig matches human rabies immunoglobulin in phase III trialRead the full article →
Cite this issue
Dr Natalya Mathur, Dr Anjali Mathur, Dr Mathur G, ENCLAI. ENCLAI Evidence Digest — September 2026. ENCLAI; 2026. https://doi.org/10.5281/zenodo.23073603. ENCLAI ID ENCLAI-2026-0000476-5.
For healthcare and research professionals. This digest summarises published evidence and is not medical advice. Every number is checked against its exact source sentence; charts are drawn by code from verified values. Report an error to [email protected]; corrections are listed in the next issue.